There’s more to blue cheese than just the stench
Marbled veins of blue line the otherwise antique white surface.
As you approach, the pungent smell fills your nostrils, akin to gym socks for some.
But there’s far more to blue cheese than just the stink. The marbled veins of blue, which are edible Penicilliummolds, produce compounds with antifungal, antibacterial, and other biological properties in high doses also known as natural products.

Virginia Tech researchers found a new, efficient way to synthesize some of these beneficial blue cheese compounds in a way that avoids the use of harmful chemicals. Previously, the synthesization of these compounds was either extremely low in yield or required the use of harmful or dangerous chemicals.
“This discovery explains the mechanism behind a new reaction in our field, filling a knowledge gap,” said Sydney Johnson Ph.D. ’24, the lead author who earned her doctorate in biochemistry.
Antibacterial resistance has become a growing problem for society, which was caused by the overuse of natural products used on the market for decades, Johnson said.
By finding a way to synthesize on a large scale a naturally occurring compound that hasn’t previously been used for antibacterial applications, Virginia Tech researchers were able to evade the existing antibacterial resistances.
“We work with an enzyme that can help create a natural product that has a unique structure that would make it very difficult for pathogens to become resistant,” Johnson said. “Existing pathogens would have to evolve to be resistant to this new compound.”
The paper was recently published in ACS Biochemistry.

“I like to train innovative scientists that work on trying to move the science forward by developing projects that move the entire field forward,” said Pablo Sobrado, professor of biochemistry who leads the Sobrado Lab and is also a researcher on the paper. “Sydney achieved that with this research.”
Enzymes are proteins that help speed up chemical reactions. For their experiment, researchers used an enzyme that produces something called roquefortine L. Parts of its chemical structure are biologically active, which means that it can have beneficial properties such as antimicrobial activities.
In addition, the production of roquefortine L is central to the production of other molecules called glandiclone, melegranin, and oxaline, which have been shown to have broad antimicrobial properties and promising anticancer effects against human breast and leukemia cancer cells.
This enzyme attaches two hydroxyl groups to a nitrogen atom, which are functional groups found in sugars and alcohols. A hydroxyl group consists of one hydrogen and one oxygen atom. Through a complex chemical process, the hydroxyl groups then develop an entirely different functionality.
“This has not been studied in detail before, and Sydney showed how the enzyme holds on first to the product that has the one hydroxyl group, attaches the second group, and then obtains the final product,” Sobrado said.
Many fungal species make this compound naturally, and it’s relatively new in the biochemistry field to research how to synthesize these processes at a large scale. According to the researchers, the reaction mechanism and the actual chemistry that takes place on the involved nitrogen atom is completely novel from other publications.
“This publication lays the foundation to utilize the enzyme to synthesize the natural products,” Johnson said. “The improvements make this process much more marketable. Eventually, we could get a drug containing one of these compounds or something similar to it to the market.”
This article is republished from the Virginia Tech News page. Read the original here.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17–21 in Cambridge, Massachusetts.